1%甲氨基阿维菌素苯甲酸盐微囊悬浮剂制备工艺研究

为促进甲氨基阿维菌素苯甲酸盐 (简称甲维盐) 微囊悬浮剂的工业化生产，以脲醛树脂为壁材，采用原位聚合法制备了1%甲维盐微囊悬浮剂，对溶剂、乳化剂及其用量、搅拌速率、酸化时间、固化温度、预聚体溶液甲醛-尿素比例 n (甲醛) : n (尿素)] 及用量等因素进行了优化。结果表明:采用m (环己酮) : m (200# 溶剂油)=1 : 2] 的复配溶剂，在复配乳化剂  m (农乳603# ) : m (农乳500# )=5 : 1] 质量分数为2.4%，搅拌速率300 r/min，调酸时间120 min，固化温度70 ℃，预聚体溶液n (甲醛) : n (尿素) 为3 : 1、质量分数20%条件下，可制得外观形态良好的甲维盐微囊，其包封率达83.8%，平均粒径为2.3 μm。经高效液相色谱法测定，证明其缓释性能良好，在测试条件下可持续释放17 d。同时，针对小菜蛾3龄幼虫的生物测定试验表明，该微囊悬浮剂具有良好的缓释杀虫活性，与对照药剂甲维盐微乳剂相比具有更长的持效期。

Preparation technology of 1% emamectin benzoate microcapsule suspensions

In order to promote the industrial production of emamectin benzoate microcapsule suspension, 1% emamectin benzoate microcapsule suspensions was prepared via in-situ polymerization process, using urea-formaldehyde resin as the wall material. The influence of solvent selection, emulsifier and its dosage, stirring rate, acidification time, curing temperature and the amount of substance ratio of prepolymer formaldehyde and urea on the performance of microcapsules was studied. Emamectin benzoate microcapsule with preferable encapsulation rate (83.8%) and average particle size (2.3 μm) was formed under the optimal conditions, when the compound emulsifier (m (603# ) : m (500# )=5 : 1) dosage was 2.4% mass fraction, the stirring rate was 300 r/min, the acidification time was 120 min, the curing temperature was 70 ℃, the amount of substance ratio of prepolymer formaldehyde and urea was 3 : 1, and the mass fraction was 20%. HPLC analysis showed that emamectin benzoate microcapsule had a favorable slow release performance, which can achieve 17-day sustained-release under test conditions. At the same time, bioassay experiments targeting the 3rd instar larvae of Plutella xylostella showed that the microcapsule suspension had good sustained-release bioactivity. And the duration was longer than the control agent.